Ireland's Life Sciences sector has grown from very humble beginnings in the 1960s to reach global significance. Collaborative clusters in Pharmaceutical, Biotechnology, Medical Devices and Diagnostics have been a key element behind the remarkable growth of a sector that directly employs 30,000 people.
The Biopharmaceutical industry has made a capital investment of approximately $10 billion in new facilities in Ireland, most of which has come in the last 10 years. This represents close to the biggest wave of investment in new BioTech facilities anywhere in the world.
10 of the top 10
7th largest exporter
€39bn in annual exports
75 pharmaceutical companies
40 FDA approved
Ireland has one of the youngest and most highly educated populations in Europe. This provides a rich and strong pool of talent for the sector, which continues to benefit from high levels of investment in third-level education and the growth of collaborative clusters.
Ireland’s universities in the fields of Engineering, Chemistry, Bio Chemistry and Bio Technology have strong cooperative links with the sector. Feedback from the industry in terms of its skills needs feeds directly into the universities and drives Ireland’s pursuit of Biopharmaceutical academic excellence.
Manufacturing excellence in Biopharmaceuticals is a hallmark of Ireland's success in the sector. This is constantly driving growth in the likes of Bio Tech, which has developed from two manufacturing sites in 2003 to 18 in 2017.
A key driver of operational and research excellence is practitioner-to-practitioner knowledge sharing. With strong clusters based in Dublin and Cork, and rapidly developing hotspots around Sligo, Waterford and Mayo, organisations, such as the Irish Centre for Business Excellence and IBEC, work with the IDA to facilitate best practice-sharing between companies.
Ireland has an exemplary compliance record with regulatory agencies, including HPRA, FDA and EMA. They work closely with companies to achieve trouble-free compliance. Certification agencies in Ireland operate in accordance with European and global standard procedures.
Ireland’s regulatory track record is excellent and the Health Product Regulatory Authority (HPRA), boasts an international reputation in regulatory compliance.
The HPRA has recently initiated Regulatory Science Ireland to explore opportunities for investment in research to increase understanding around processes and products, and thereby support Ireland’s reputation for regulatory excellence in manufacturing.
Ireland has a significant track record of clinical and academic research excellence. The government has also committed €8 billion to research funding to further bolster Ireland’s reputation as a growing hub for research and development.
The National Institute for Bioprocess Research and Training (NIBRT), created from a €60million investment by the IDA, gave practical training to 2,000 people in 2013. Senior executives from the sector sit on the NIBRT board in the knowledge that the availability of suitably trained staff is a key determinant of success in Biopharmaceutical manufacturing.
Science Foundation Ireland (SFI) funds a lot of basic research in the Biopharmaceutical sector, especially with regards to understanding cancer, autoimmune disease and Alzheimer’s. Recently SFI announced a deal with Pfizer, whereby both parties are jointly funding basic Bio Medical research, which will help support Pfizer’s drug discovery efforts here in Ireland and globally.
Explore the current business landscape in Ireland and see what's happening on the ground now.
Move to new, larger premises in Waterford signals company’s plans to develop a flagship facility to spearhead its activities in Ireland and worldwide
Agilent Technologies Ireland Ltd. today held the official opening of a new, purpose-built research and development extension to its Little Island, County Cork facility.
Shire held an official site dedication event at its new state of-the-art biologics facility in Dunboyne, Co. Meath today.
Development of the 120-acre site has been underway since November 2017. Approximately 400 people will be employed at the facility when it is at full capacity.
ILC Dover, a global leader in flexible containment solutions for the pharmaceutical and biopharmaceutical industry today announced it is expanding its Irish production footprint by opening a location in Blarney, County Cork, Ireland creating up to 70 jobs over two years.
Biotechnology company Regeneron had two reasons to be cheerful after the inaugural Invest in Ireland Awards in October. The company came away with the Grand Prix and also won the ‘Excellence in Regional Investment’ category. The recognition follows five years of expansion in Ireland since the company first announced its presence here in 2013.
The 29th of March next year is a critical date for U.S. biotech companies because business as usual disappears in Europe as a result of Brexit. Long a favored location for manufacturing and selling pharmaceuticals and devices across Europe, the United Kingdom will no longer be part of the EU and so free trade across Europe will change. American firms with UK operations should have already devised a post-Brexit strategy and begun implementing it given the fact that the changeover is just a few months away.
An Taoiseach Leo Varadkar TD, Minister for Business, Enterprise and Innovation Heather Humphreys TD and IDA Ireland today welcomed the announcement that MSD is to construct a second manufacturing facility at its existing site in Carlow with the creation of 170 new jobs.
Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced National Technology Park, Castletroy, Limerick, as the location of its new permanent facility which is expected to manufacture delivery components for its transcatheter heart valve therapies.
BioMarin International Ltd. is investing in a new Drug Product Filling Project at its Shanbally, Co. Cork facility. This project will allow the company to maximise the flexibility of the site with the expansion of the operational manufacturing capacity to meet the rise in the global demand for its therapies to treat rare genetic diseases that mostly affect children.
IDA Ireland welcomes today’s statement from Abbott in Donegal that it is to expand its existing manufacturing facility which will result in the creation of c.500 new jobs over the next number of years.
The newest drugs emerging in the market for gene and cell therapy as well as disposables have become the focus area for U.S. bioprocessing firms, many of whom have been moving some production overseas -- particularly to Europe. But while single-use products have advantages in production costs and turnaround time, there are also some challenges for American biopharma companies in choosing their optimal overseas location.
Phibro Animal Health Corporation (Nasdaq:PAHC) today announced plans to establish a biotech facility producing a range of innovative animal health vaccines on the IDA Ireland Finisklin Business Park in Sligo, creating up to 150 jobs over 5 years.
IDA Ireland, the inward investment agency of the Irish Government has today reported a very strong first half of 2018.
An Taoiseach Leo Varadkar, Prime Minister of Ireland today announced that WuXi Biologics, a Hong Kong-listed (2269.HK) global open-access biologics technology platform company, is to invest €325 million and create 400 new jobs over five years in a new biologics drug substance manufacturing facility on the Industrial Development Authority’s (IDA) greenfield site in Mullagharlin in Dundalk, Co. Louth.
IDA Ireland today congratulated leading pharmaceutical outsourcing services provider PCI Pharma Services (PCI) on the launch of its new contained packaging facility for the primary and secondary packaging of highly potent products at its newly acquired site in Drogheda, Co. Louth. The new facility will lead to the creation of more than 70 new jobs over the next five years while 50 new jobs will be created at its facility in Stamullen, Co. Meath. PCI has added c.30 positions at the Drogheda facility since its acquisition of Millmount Healthcare last year.
Ministers Humphreys and Breen and IDA Ireland welcome project with expected investment totaling €80m and 600 jobs
Tuesday, 13th February 2018 – Minister for Business, Enterprise and Innovation Heather Humphreys TD and IDA Ireland today welcomed theat announcement that MSD is to develop a new biotechnology facility in Dublin, with the expected creation of up to 350 new jobs.
Known as MSD Biotech, Dublin, the facility will be constructed on an existing MSD-owned property, the site of its former facility in Swords, Co. Dublin.
The Irish and South Korean flags will be ceremoniously raised today in the grounds of a pharmaceuticals manufacturing campus in Swords, Co. Dublin, which has been acquired by SK biotek, a global life sciences company, the first Korean pharma-company to invest in Ireland.
19,851 Jobs Created in FDI companies – third consecutive year of strong growth under current strategy
Explore the current business landscape in Ireland and see what's happening on the ground now.
You'll find us responsive to your needs, proactive, professional and willing to go the extra mile.
We have 28 Offices worldwide helping support companies expand their operations in Ireland.